DNLI Earnings & Financial Statements
Denali Therapeutics Inc.
$17.87
-$0.53(-2.88%)
39
Overall
60
Value
18
Tech
39
Quality
Market Cap
$2.86B
Volume
2.70M
52W Range
$13.75 - $27.30
Target Price
$35.41
DNLI earnings and financial statements: Denali Therapeutics Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
DNLI Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | $330.53M | $108.46M | $48.66M |
| Operating income | -$555.34M | -$487.34M | -$196.70M | -$340.74M | -$295.75M |
| EBITDA | -$507.88M | -$463.37M | -$172.45M | -$315.57M | -$287.16M |
| Net income | -$512.54M | -$422.77M | -$145.22M | -$325.99M | -$290.58M |
| EPS (diluted) | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$412.60M | -$347.69M | -$357.99M | -$244.72M | -$211.39M |
| Capital expenditure | -$9.50M | -$15.91M | -$12.94M | -$17.83M | -$8.50M |
| Free cash flow | -$422.10M | -$363.61M | -$370.93M | -$262.55M | -$219.89M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DNLI | $17.87 | -2.9% | 2.70M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Denali Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW